Inside the Clinic: Updates in Diagnosis, Treatment, and Management of Chronic Graft-Versus-Host Disease : Episode 6
Ibrutinib’s Approval and Use in Chronic Graft-Versus-Host Disease
Corey Cutler, MD, MPH, FRCPC, breaks down the mechanism of action and FDA approval of ibrutinib, a BTK inhibitor, in chronic graft-versus-host disease.
EP: 1.Background on Graft-vs-Host Disease: Risk Factors and Prevention
EP: 2.Acute vs Chronic GVHD: Identification and Stratification
EP: 3.Frontline Treatment Options for Chronic GVHD
EP: 4.Defining Steroid-Refractory and Steroid-Dependent GVHD
EP: 5.Identifying and Managing Steroid-Refractory Chronic GVHD
Now Viewing
EP: 6.Ibrutinib’s Approval and Use in Chronic Graft-Versus-Host Disease
EP: 7.Belumosudil’s Approval and Use in Chronic Graft-Vs-Host Disease
EP: 8.Mechanism of Action of Ruxolitinib
EP: 9.REACH3 Trial: Approval of Ruxolitinib in Chronic GVHD
EP: 10.Chronic GVHD: Real-World Use of Ruxolitinib
EP: 11.Selecting Second-Line Therapy for Chronic GVHD
EP: 12.Chronic GVHD: Novel Treatment Approaches With Approved Agents
EP: 13.Novel Targeted Agents in GVHD: The FLIGHT and AGAVE-201 Trials
EP: 14.HSCT Approaches to Retain GVL While Preventing GVHD
EP: 15.Emerging Treatment Strategies for Chronic GVHD
Related Videos
Related Content
